Nanexa

1.87 SEK

+2.74 %

Less than 1K followers

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+2.74 %

+5.88 %

-21.67 %

-10.64 %

-13.33 %

-26.01 %

+7.71 %

-86.46 %

-77.12 %

Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.

Market cap

297.04M SEK

Turnover

398.24K SEK

Revenue

24.36M

EBIT %

-106.98 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19/2

2026

Annual report '25

29/4

2026

Interim report Q1'26

27/8

2026

Interim report Q2'26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Third party research11/7/2025, 8:58 AM

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Press release11/7/2025, 7:00 AM

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Regulatory press release11/6/2025, 7:00 AM

Nanexa publicerar delårsrapport för januari-september 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/6/2025, 7:00 AM

Nanexa publishes interim report for January-September 2025

Press release10/16/2025, 6:25 AM

Nanexa utvalt som finalist i Fierce Innovation Awards Life Sciences Edition 2025

Press release10/16/2025, 6:25 AM

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Regulatory press release10/1/2025, 10:40 AM

Nanexa AB byter Certified Adviser till Tapper Partners AB

Regulatory press release10/1/2025, 10:40 AM

Nanexa AB changes Certified Adviser to Tapper Partners AB

Press release9/22/2025, 6:00 AM

Nanexa erhåller japanskt patentgodkännande för specifik PharmaShell-struktur

Press release9/22/2025, 6:00 AM

Nanexa receives Japanese patent approval for specific PharmaShell structure

Third party research8/28/2025, 6:09 AM

Nanexa: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Emergers

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly liraglutide exposure over 36 days without significant gastrointestinal side effects. The company also gained industry...

Press release8/28/2025, 6:00 AM

Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Regulatory press release8/27/2025, 5:00 AM

Nanexa publicerar delårsrapport för januari-juni 2025

Regulatory press release8/27/2025, 5:00 AM

Nanexa publishes interim report for January-June 2025

Press release8/8/2025, 8:43 AM

Nanexa tecknar förlängning av utvärderingsavtal med ett stort läkemedelsföretag för att undersöka PharmaShell®-formuleringar med långverkande effekt för en flera miljarder USD stor marknad

Press release8/8/2025, 8:43 AM

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

Press release6/24/2025, 6:00 AM

Presentation av NEX-22 fas I data: En enmånads GLP-1-injektion väcker positiv respons vid ADA:s 85:e vetenskapliga möte i Chicago

Press release6/24/2025, 6:00 AM

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Press release6/3/2025, 1:10 PM

Nanexa lyfter fram NEX-22 och PharmaShell® i en intensiv internationell exponeringsperiod

Press release6/3/2025, 1:10 PM

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.